Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

USP15 antagonizes CRL4 CRBN -mediated ubiquitylation of glutamine synthetase and neosubstrates
Thang Van Nguyen
Proceedings of the National Academy of Sciences (2021) Vol. 118, Iss. 40
Open Access | Times Cited: 35

Showing 1-25 of 35 citing articles:

An overview of PROTACs: a promising drug discovery paradigm
Liu Zi, Mingxing Hu, Yang Yu, et al.
Molecular Biomedicine (2022) Vol. 3, Iss. 1
Open Access | Times Cited: 156
Overcoming Cancer Drug Resistance Utilizing PROTAC Technology
Matthew R. Burke, Alexis R. Smith, Guangrong Zheng
Frontiers in Cell and Developmental Biology (2022) Vol. 10
Open Access | Times Cited: 71
Advancing Strategies for Proteolysis-Targeting Chimera Design
Minglei Li, Ying Zhi, Bo Liu, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 4, pp. 2308-2329
Closed Access | Times Cited: 46
Ubiquitination and deubiquitination in cancer: from mechanisms to novel therapeutic approaches
Fangfang Liu, Jingyu Chen, Kai Li, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 41
PROTACs: Current and Future Potential as a Precision Medicine Strategy to Combat Cancer
Kailee A. Rutherford, Kirk J. McManus
Molecular Cancer Therapeutics (2024) Vol. 23, Iss. 4, pp. 454-463
Open Access | Times Cited: 17
Applications of protein ubiquitylation and deubiquitylation in drug discovery
Yilin Chen, Haoan Xue, Jianping Jin
Journal of Biological Chemistry (2024) Vol. 300, Iss. 5, pp. 107264-107264
Open Access | Times Cited: 17
Drug resistance mechanisms and treatment strategies mediated by Ubiquitin-Specific Proteases (USPs) in cancers: new directions and therapeutic options
Hongli Gao, Zhuo Xi, Jingwei Dai, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 17
The importance of cellular degradation kinetics for understanding mechanisms in targeted protein degradation
Kristin M. Riching, Elizabeth A. Caine, Marjeta Urh, et al.
Chemical Society Reviews (2022) Vol. 51, Iss. 14, pp. 6210-6221
Open Access | Times Cited: 39
Degradation of Hexokinase 2 Blocks Glycolysis and Induces GSDME-Dependent Pyroptosis to Amplify Immunogenic Cell Death for Breast Cancer Therapy
Ruoxi Sang, Renming Fan, Aohua Deng, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 13, pp. 8464-8483
Closed Access | Times Cited: 29
The emerging roles of non-canonical ubiquitination in proteostasis and beyond
Yoshino Akizuki, Stephanie Kaypee, Fumiaki Ohtake, et al.
The Journal of Cell Biology (2024) Vol. 223, Iss. 5
Open Access | Times Cited: 10
Modulating the phosphorylation status of target proteins through bifunctional molecules
Qindi He, Zhijie Wang, Rongrong Wang, et al.
Drug Discovery Today (2025), pp. 104307-104307
Closed Access | Times Cited: 1
Ubiquitination Links DNA Damage and Repair Signaling to Cancer Metabolism
Seo-Young Koo, Eun‐Ji Park, Hyun-Ji Noh, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 9, pp. 8441-8441
Open Access | Times Cited: 20
USP15 in Cancer and Other Diseases: From Diverse Functionsto Therapeutic Targets
Yan-Chi Li, Songwang Cai, Yu-Bin Shu, et al.
Biomedicines (2022) Vol. 10, Iss. 2, pp. 474-474
Open Access | Times Cited: 23
CRISPR/Cas9-based genome-wide screening for deubiquitinase subfamily identifies USP1 regulating MAST1-driven cisplatin-resistance in cancer cells
Apoorvi Tyagi, Kamini Kaushal, Arun Pandian Chandrasekaran, et al.
Theranostics (2022) Vol. 12, Iss. 13, pp. 5949-5970
Open Access | Times Cited: 23
Lenalidomide in Multiple Myeloma: Review of Resistance Mechanisms, Current Treatment Strategies and Future Perspectives
Piotr Kulig, Sławomir Milczarek, Estera Bakinowska, et al.
Cancers (2023) Vol. 15, Iss. 3, pp. 963-963
Open Access | Times Cited: 13
Role of Ubiquitination-driven Metabolisms in Oncogenesis and Cancer Therapy
Dongqin Yang, Can Yang, Linlin Huang, et al.
Seminars in Cancer Biology (2025)
Closed Access
HDAC6 and USP9X Control Glutamine Metabolism by Stabilizing GS to Promote Glioblastoma Tumorigenesis
Go Woon Kim, Minhae Cha, Hien Thi My Ong, et al.
Advanced Science (2025)
Open Access
Therapeutic potential of targeting ubiquitin-specific proteases in colorectal cancer
Chern Ein Oon, Padmanabhan Anbazhagan, Chong Teik Tan
Drug Discovery Today (2025), pp. 104356-104356
Closed Access
Cellular parameters shaping pathways of targeted protein degradation
A.G. Cardno, Bryony G. Kennedy, Catherine Lindon
Communications Biology (2025) Vol. 8, Iss. 1
Open Access
Regulation of Glucose, Fatty Acid and Amino Acid Metabolism by Ubiquitination and SUMOylation for Cancer Progression
Shunqin Zhu, Hongyu Gu, Cheng Peng, et al.
Frontiers in Cell and Developmental Biology (2022) Vol. 10
Open Access | Times Cited: 18
CRISPR/Cas9-based genome-wide screening of the deubiquitinase subfamily identifies USP3 as a protein stabilizer of REST blocking neuronal differentiation and promotes neuroblastoma tumorigenesis
Janardhan Keshav Karapurkar, Min-Seong Kim, Jencia Carminha Colaco, et al.
Journal of Experimental & Clinical Cancer Research (2023) Vol. 42, Iss. 1
Open Access | Times Cited: 9
Targeting the ubiquitin pathway in lymphoid malignancies
Boheng Li, Pieter J.A. Eichhorn, Wee Joo Chng
Cancer Letters (2024) Vol. 594, pp. 216978-216978
Open Access | Times Cited: 3
Ablation of the deubiquitinase USP15 ameliorates nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
Jung-Hwan Baek, Myung Sup Kim, Hye Ryeon Jung, et al.
Experimental & Molecular Medicine (2023) Vol. 55, Iss. 7, pp. 1520-1530
Open Access | Times Cited: 8
A small-molecule degrader selectively inhibits the growth of ALK-rearranged lung cancer with ceritinib resistance
Xin Li, Zixiong Wang, Chao Chen, et al.
iScience (2024) Vol. 27, Iss. 2, pp. 109015-109015
Open Access | Times Cited: 2
Mezigdomide—A Novel Cereblon E3 Ligase Modulator under Investigation in Relapsed/Refractory Multiple Myeloma
Monique Hartley-Brown, Clifton C. Mo, Omar Nadeem, et al.
Cancers (2024) Vol. 16, Iss. 6, pp. 1166-1166
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top